BridgeBio

Cardiology

First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM – BridgeBio

Written by Charlie King | 20 Sep 2026

BridgeBio Pharma, Inc. announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to further characterize the long-term effects of acoramidis on the… read more.
Cardiology

Acoramidis continues to demonstrate disease-modifying effects in ATTR-CM, reducing sTTR variability and outpatient worsening heart failure – BridgeBio

Written by Charlie King | 23 May 2026

BridgeBio Pharma, Inc. announced new data from the Phase III ATTRibute-CM study at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology… read more.
Cardiology

Acoramidis significantly reduces the risk of all-cause and cardiovascular mortality in patients with ATTR-CM through month 54 – BridgeBio

Written by Charlie King | 7 May 2026

BridgeBio Pharma, Inc. presented long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial, demonstrating sustained clinical benefit of acoramidis through Month 54 in patients with… read more.